In8Bio Inc (INAB)

$1.50 +0.08 (5.63%)
Market Cap 14.77M
Revenue (ttm) 0.00
Net Income (ttm) -19.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 47,000
Avg Vol 60,636
Day's Range N/A - N/A
Shares Out 9.85M
Stochastic %K 68%
Beta 0.04
Analysts Strong Sell
Price Target $5.00

Company Profile

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an alloge...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 600 6438
Website: in8bio.com
Address:
350 5th Avenue, Suite 5330, New York, United States
Royal_Imperial
Royal_Imperial Apr. 24 at 9:38 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $MODD $INAB $KEEL $DRMA $WW/...
1 ¡ Reply
aletz
aletz Apr. 22 at 2:37 PM
$INAB https://www.youtube.com/watch?v=xThHoXfV2lE Latest presentation by CEO William Ho: Here are a few notable updates on upcoming catalysts: 1) R&D Day is scheduled for May 21st. 2) TCE Mice data is expected between Q3 and Q4. 3) An AML update will be presented at ASH in December. 4) A peer-reviewed publication on GBM and FDA guidance is expected in near future. I look forward to seeing some meaningful updates on R&D Day next month.
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 10:54 PM
$INAB RSI: 52.73, MACD: -0.0881 Vol: 0.15, MA20: 1.48, MA50: 1.66 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
aletz
aletz Apr. 8 at 5:59 PM
$INAB https://www.redchip.com/webinar/redchip/84347130169
0 ¡ Reply
IN8bio
IN8bio Apr. 7 at 5:07 PM
Save the Date: May 21 2026 We’ll be hosting our R&D Day with updates on our: • Glioblastoma (GBM) program • Gamma-delta T cell engager platform Virtual option available 👇 🔗 Register today by visiting https://investors.in8bio.com and navigating to the “Events and Presentations” section. $INAB
0 ¡ Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Apr. 7 at 4:22 PM
$INAB
0 ¡ Reply
IN8bio
IN8bio Apr. 6 at 3:58 PM
Biotech = cycles Capital = follows what’s working Our CEO on GLP-1s + where innovation fits 👇 Listen here: •https://open.spotify.com/episode/7pV0sl2dLbAKHMaoxw5LqI?si=EhVs_3pjS5mHKnh877Qm1Q&nd=1&dlsi=260b7b0600c348d6 •https://raisingbiotech.com/episode/s4-e4-the-weight-of-the-moment-how-glp-1s-are-rewiring-biotech-investing-expert-analysis •https://podcasts.apple.com/us/podcast/s4 $INAB
0 ¡ Reply
IN8bio
IN8bio Apr. 2 at 3:20 PM
Solid tumors have been one of the toughest challenges in oncology. New science is starting to change that. Great to see our work featured by Genetic Engineering & Biotechnology News! 🔗 https://www.genengnews.com/topics/cancer/engineering-biology-to-fight-cancer/ $INAB
0 ¡ Reply
3ARated
3ARated Mar. 31 at 9:40 PM
$INAB Green, I say, Green!
0 ¡ Reply
HumbledBull
HumbledBull Mar. 30 at 3:52 PM
$INAB This is in a free fall with no volume.
0 ¡ Reply
Latest News on INAB
IN8bio Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 10:30 AM EDT - 9 days ago

IN8bio Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 3, 2026, 4:00 PM EDT - 22 days ago

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

Mar 12, 2026, 4:01 PM EDT - 6 weeks ago

IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026

IN8bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:50 AM EST - 7 weeks ago

IN8bio Transcript: TD Cowen 46th Annual Health Care Conference

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

IN8bio to Present at TD Cowen 46th Annual Health Care Conference

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

Feb 9, 2026, 8:00 AM EST - 2 months ago

IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer

IN8bio Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference

Feb 5, 2026, 3:00 PM EST - 2 months ago

IN8bio Transcript: Noble Capital Markets’ Emerging Growth Virtual Equity Conference

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

Feb 3, 2026, 8:00 AM EST - 2 months ago

IN8bio to Present at Upcoming Investor and Scientific Conferences in February

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

Jan 12, 2026, 8:00 AM EST - 3 months ago

IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

Dec 19, 2025, 8:00 AM EST - 4 months ago

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 4:00 PM EST - 6 months ago

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

Oct 29, 2025, 8:00 AM EDT - 6 months ago

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

Oct 27, 2025, 8:00 AM EDT - 6 months ago

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 4:00 PM EDT - 9 months ago

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

Jun 9, 2025, 7:00 AM EDT - 11 months ago

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

Jun 2, 2025, 7:30 AM EDT - 11 months ago

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

May 12, 2025, 8:00 AM EDT - 1 year ago

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 4:00 PM EDT - 1 year ago

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Mar 18, 2025, 8:05 AM EDT - 1 year ago

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 13, 2025, 4:05 PM EDT - 1 year ago

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 10:30 AM EST - 1 year ago

IN8bio Transcript: TD Cowen 45th Annual Healthcare Conference

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

Mar 3, 2025, 9:28 AM EST - 1 year ago

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 11:00 AM EST - 1 year ago

IN8bio Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

Feb 14, 2025, 9:00 AM EST - 1 year ago

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio Transcript: Study Result

Feb 11, 2025, 8:30 AM EST - 1 year ago

IN8bio Transcript: Study Result

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

Feb 11, 2025, 8:00 AM EST - 1 year ago

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio Transcript: Biotech Showcase 2025

Jan 14, 2025, 5:00 PM EST - 1 year ago

IN8bio Transcript: Biotech Showcase 2025

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

Dec 10, 2024, 7:00 AM EST - 1 year ago

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Nov 12, 2024, 4:26 PM EST - 1 year ago

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 2:30 PM EDT - 1 year ago

IN8bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Sep 4, 2024, 4:01 PM EDT - 1 year ago

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 6:05 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Aug 12, 2024, 8:05 AM EDT - 1 year ago

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

IN8bio Transcript: H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 25, 2024, 2:30 PM EDT - 1 year ago

IN8bio Transcript: H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 1 year ago

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

Jun 13, 2024, 4:01 PM EDT - 2 years ago

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

Jun 3, 2024, 6:05 AM EDT - 2 years ago

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

May 24, 2024, 8:00 AM EDT - 2 years ago

IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

May 23, 2024, 5:00 PM EDT - 2 years ago

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

May 14, 2024, 10:00 AM EDT - 2 years ago

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

May 13, 2024, 8:00 AM EDT - 2 years ago

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

May 9, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

Apr 30, 2024, 6:05 AM EDT - 2 years ago

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Apr 16, 2024, 4:05 PM EDT - 2 years ago

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

Apr 9, 2024, 4:30 PM EDT - 2 years ago

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Mar 14, 2024, 4:00 PM EDT - 2 years ago

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

IN8bio to Present at Upcoming Investor Conferences

Feb 26, 2024, 8:00 AM EST - 2 years ago

IN8bio to Present at Upcoming Investor Conferences

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Feb 14, 2024, 8:00 AM EST - 2 years ago

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Jan 4, 2024, 8:00 AM EST - 2 years ago

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Dec 11, 2023, 4:05 PM EST - 2 years ago

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Dec 11, 2023, 9:00 AM EST - 2 years ago

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

IN8bio Transcript: B. Riley Securities' 3rd Annual Oncology Conference

Jan 18, 2023, 12:00 PM EST - 3 years ago

IN8bio Transcript: B. Riley Securities' 3rd Annual Oncology Conference

Royal_Imperial
Royal_Imperial Apr. 24 at 9:38 PM
MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $MODD $INAB $KEEL $DRMA $WW/...
1 ¡ Reply
aletz
aletz Apr. 22 at 2:37 PM
$INAB https://www.youtube.com/watch?v=xThHoXfV2lE Latest presentation by CEO William Ho: Here are a few notable updates on upcoming catalysts: 1) R&D Day is scheduled for May 21st. 2) TCE Mice data is expected between Q3 and Q4. 3) An AML update will be presented at ASH in December. 4) A peer-reviewed publication on GBM and FDA guidance is expected in near future. I look forward to seeing some meaningful updates on R&D Day next month.
0 ¡ Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 10:54 PM
$INAB RSI: 52.73, MACD: -0.0881 Vol: 0.15, MA20: 1.48, MA50: 1.66 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
aletz
aletz Apr. 8 at 5:59 PM
$INAB https://www.redchip.com/webinar/redchip/84347130169
0 ¡ Reply
IN8bio
IN8bio Apr. 7 at 5:07 PM
Save the Date: May 21 2026 We’ll be hosting our R&D Day with updates on our: • Glioblastoma (GBM) program • Gamma-delta T cell engager platform Virtual option available 👇 🔗 Register today by visiting https://investors.in8bio.com and navigating to the “Events and Presentations” section. $INAB
0 ¡ Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Apr. 7 at 4:22 PM
$INAB
0 ¡ Reply
IN8bio
IN8bio Apr. 6 at 3:58 PM
Biotech = cycles Capital = follows what’s working Our CEO on GLP-1s + where innovation fits 👇 Listen here: •https://open.spotify.com/episode/7pV0sl2dLbAKHMaoxw5LqI?si=EhVs_3pjS5mHKnh877Qm1Q&nd=1&dlsi=260b7b0600c348d6 •https://raisingbiotech.com/episode/s4-e4-the-weight-of-the-moment-how-glp-1s-are-rewiring-biotech-investing-expert-analysis •https://podcasts.apple.com/us/podcast/s4 $INAB
0 ¡ Reply
IN8bio
IN8bio Apr. 2 at 3:20 PM
Solid tumors have been one of the toughest challenges in oncology. New science is starting to change that. Great to see our work featured by Genetic Engineering & Biotechnology News! 🔗 https://www.genengnews.com/topics/cancer/engineering-biology-to-fight-cancer/ $INAB
0 ¡ Reply
3ARated
3ARated Mar. 31 at 9:40 PM
$INAB Green, I say, Green!
0 ¡ Reply
HumbledBull
HumbledBull Mar. 30 at 3:52 PM
$INAB This is in a free fall with no volume.
0 ¡ Reply
SkywalkerAR
SkywalkerAR Mar. 27 at 8:28 AM
$INAB
0 ¡ Reply
SkywalkerAR
SkywalkerAR Mar. 27 at 7:16 AM
$INAB
0 ¡ Reply
you_no
you_no Mar. 27 at 5:43 AM
$INAB So, another round of dilution is coming? Correct me if I’m wrong. When are we finally going to see some actual good news? It’s about time you give something back to the people who put their trust and money into this company.
1 ¡ Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Mar. 26 at 5:07 PM
$INAB
1 ¡ Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Mar. 26 at 5:07 PM
$INAB
0 ¡ Reply
SkywalkerAR
SkywalkerAR Mar. 26 at 4:18 PM
$INAB WHAT IS THIS FREE FALL?
1 ¡ Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Mar. 25 at 12:08 AM
$INAB
0 ¡ Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Mar. 24 at 11:28 PM
$INAB
0 ¡ Reply
pkbull
pkbull Mar. 24 at 11:23 PM
$INAB so what caused the after hours pop? It’s been going down on a pretty low volume.
1 ¡ Reply
Aburose
Aburose Mar. 24 at 11:21 PM
$INAB tomorrow massive movement
0 ¡ Reply
Aburose
Aburose Mar. 24 at 11:02 PM
$INAB strong to ignore
0 ¡ Reply
Aburose
Aburose Mar. 24 at 10:57 PM
$INAB IN8BIO Inc. publishes corporate presentation on gamma-delta T cell therapies in oncology and autoimmune diseases
2 ¡ Reply